Inova Pharmaceuticals(singapore) PT

Inova Pharmaceuticals (Singapore) Pte. Limited, established on November 23, 2006, is a private company headquartered at 1 Temasek Avenue, #04-01, Millenia Tower, Singapore 039192. The company specializes in the sales and marketing of Western medicinal and pharmaceutical products, focusing on both consumer health brands and prescription medicines. Its portfolio spans key therapeutic areas such as throat, cough, cold & flu, skin care, sun care, pain management, wound care, weight management, and natural health supplements. Operating across over 75 markets, Inova Pharmaceuticals emphasizes innovative healthcare solutions to enhance global health and well-being. (companies.sg)

While specific details about Inova Pharmaceuticals' warehouse locations and logistics capabilities are not publicly disclosed, the company's extensive distribution network across over 75 markets suggests a robust infrastructure. This network likely includes strategically located warehouses and efficient logistics operations to ensure timely delivery of pharmaceutical products. The geographic coverage spans Asia, Australia, New Zealand, the Middle East, Africa, and Europe, indicating a well-established and expansive distribution system. (inovapharma.asia)

Inova Pharmaceuticals (Singapore) Pte. Limited functions primarily as a wholesaler and distributor within Singapore's pharmaceutical supply chain. The company imports finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, from India, and subsequently distributes these products to various stakeholders in the healthcare sector. This role positions Inova Pharmaceuticals as a key intermediary between international manufacturers and the local market, facilitating the availability of diverse pharmaceutical products in Singapore.

Inova Pharmaceuticals' sourcing strategy reveals a concentrated dependency on a limited number of products imported from India. The company's total import value from India stands at $636,000 USD, encompassing 61 shipments of two distinct products across two therapeutic categories. The top five products imported include Extract ($402,000 USD) and Bromhexine ($234,000 USD), accounting for 3.3% and 1.4% of the total import value, respectively. This concentration indicates a strategic choice to focus on specific high-demand products, potentially streamlining operations and strengthening supplier relationships. However, such dependency may also pose risks related to supply chain disruptions or market fluctuations affecting these particular products.

The resilience of Inova Pharmaceuticals' supply chain, particularly concerning its Indian suppliers, is not explicitly detailed in the available data. The company's concentrated sourcing strategy suggests a reliance on specific suppliers for its key products. While this focus can lead to stronger partnerships and potentially better terms, it also exposes the company to risks associated with supply chain disruptions, such as production delays or regulatory changes in India. The lack of publicly available information on backup suppliers and the diversity of formulations imported makes it challenging to fully assess the supply chain's resilience.

Inova Pharmaceuticals' concentrated sourcing pattern positions the company to leverage strong relationships with its Indian suppliers, potentially securing favorable terms and ensuring consistent product quality. This strategy may enhance operational efficiency and market responsiveness. For Indian exporters, understanding Inova Pharmaceuticals' focus on specific products and therapeutic categories presents an opportunity to align their offerings accordingly, potentially becoming preferred suppliers. However, Indian exporters should also be mindful of the risks associated with such concentration, including the impact of any supply chain disruptions or changes in market demand for these products.

In Singapore, the Health Sciences Authority (HSA) is the primary regulatory body overseeing the importation, supply, and manufacture of health products, including pharmaceuticals. Established as a statutory board under the Ministry of Health, HSA ensures that all health products meet standards of safety, quality, and efficacy. The regulatory framework governing pharmaceutical imports includes the Health Products Act and the Medicines Act, along with their subsidiary legislation, which may encompass requirements for product registration and dealer's licensing. (moh.gov.sg)

Importers of pharmaceutical products into Singapore must comply with the Health Products Act and the Medicines Act, which require product registration and dealer's licensing. The Health Sciences Authority (HSA) evaluates and approves all medicines, including generics, for safety, quality, efficacy, and compliance with Good Distribution Practice standards before they can be supplied in Singapore. Recognized Good Manufacturing Practice (GMP) certifications, such as EU GMP, WHO GMP, or PIC/S, are essential for ensuring product quality and are typically required for importation. (moh.gov.sg)

Pharmaceutical products imported into Singapore must undergo batch testing to ensure they meet the required safety, quality, and efficacy standards. Stability studies are conducted to determine the product's shelf life and storage conditions. Labeling requirements include providing information in English, detailing the product's name, active ingredients, dosage form, strength, batch number, manufacturing date, expiry date, storage conditions, and the manufacturer's details. Serialization mandates may apply to facilitate traceability and prevent counterfeit products, ensuring patient safety and product integrity.

As of August 2024, the Health Sciences Authority (HSA) has been encouraging the importation of generic medicines into Singapore after the original patents have expired. All medicines, including generics, must be evaluated and approved by HSA for safety, quality, efficacy, and compliance with Good Distribution Practice standards before they can be supplied in Singapore. This policy aims to enhance the availability of affordable medications while maintaining high standards of public health. (moh.gov.sg)

Inova Pharmaceuticals' focus on Ayurvedic & Herbal Products (63.2%) and Respiratory & OTC (36.8%) therapeutic categories aligns with market demand for natural and over-the-counter remedies. The top five imported products, including Extract ($402,000 USD) and Bromhexine ($234,000 USD), reflect this strategic emphasis. The substantial import value of these products indicates a strong market presence and consumer preference for these therapeutic areas. This strategy positions Inova Pharmaceuticals to cater to the growing demand for holistic and accessible healthcare solutions in Singapore.

Inova Pharmaceuticals' sourcing strategy is centered on importing finished pharmaceutical formulations from India, focusing on specific products within the Ayurvedic & Herbal and Respiratory & OTC categories. This approach suggests a preference for established products with proven efficacy and market acceptance. The company's reliance on Indian suppliers indicates a strategic choice to leverage India's manufacturing capabilities and cost advantages. However, the concentrated nature of this sourcing strategy may expose Inova Pharmaceuticals to risks associated with supply chain disruptions or changes in market demand for these specific products.

Based on its product mix, Inova Pharmaceuticals primarily serves the retail pharmacy and over-the-counter (OTC) segments of the Singapore market. The emphasis on Ayurvedic & Herbal Products and Respiratory & OTC categories positions the company to meet the needs of consumers seeking accessible and natural healthcare solutions. By focusing on these segments, Inova Pharmaceuticals aligns its offerings with consumer preferences for holistic and self-care remedies, enhancing its presence in the competitive pharmaceutical market.

There is a realistic opportunity for new Indian suppliers to collaborate with Inova Pharmaceuticals, particularly those offering products within the Ayurvedic & Herbal and Respiratory & OTC categories. By aligning their offerings with Inova Pharmaceuticals' strategic focus, Indian exporters can position themselves as potential suppliers. However, the concentrated nature of Inova Pharmaceuticals' sourcing strategy suggests that any new supplier would need to demonstrate a strong value proposition, including product quality, regulatory compliance, and competitive pricing, to establish a successful partnership.

Indian exporters seeking to supply Inova Pharmaceuticals must ensure their products are registered with the Health Sciences Authority (HSA) in Singapore and comply with the Health Products Act and the Medicines Act. Possessing recognized Good Manufacturing Practice (GMP) certifications, such as EU GMP, WHO GMP, or PIC/S, is essential to meet quality standards. Additionally, products must undergo batch testing, stability studies, and adhere to labeling requirements in English, as specified by HSA regulations. Compliance with these standards is crucial for successful market entry and distribution in Singapore.

To establish a relationship with Inova Pharmaceuticals, Indian exporters should first ensure their products meet all regulatory requirements set by the Health Sciences Authority (HSA) in Singapore. Engaging in direct communication with Inova Pharmaceuticals to understand their specific product needs and quality expectations is essential. Participating in relevant industry trade fairs and networking events can provide opportunities to showcase products and build connections. Developing a comprehensive regulatory filing strategy, including obtaining necessary certifications and approvals, will facilitate the importation process. Setting realistic timelines for product registration and market entry, considering HSA's processing times and any additional requirements, will aid in planning and execution.